why is biolase stock down

One of the reasons why the stock price is down today likely has to do with a correction following a surge of over 258% over the past month. Yesterday alone, the stock price of BIOLASE increased by over 80%. That surge had to do with the company signing an agreement with Dental Care Alliance (DCA).

Full Answer

Should you buy BIOLASE stock?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BIOLASE stock. View analyst ratings for BIOLASE or view top-rated stocks.

How did BIOLASE's stock split work?

How did BIOLASE's stock split work? BIOLASE's stock reverse split before market open on Friday, May 11th 2018. The 1-5 reverse split was announced on Thursday, May 10th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 10th 2018.

What are BIOLASE's price targets for the next 12 months?

3 equities research analysts have issued 12-month price objectives for BIOLASE's shares. Their forecasts range from $1. 15 to $3. 00. On average, they expect BIOLASE's share price to reach $2. 05 in the next twelve months. This suggests a possible upside of 416. 4% from the stock's current price.

What other companies does BIOLASE own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BIOLASE investors own include Himax Technologies (HIMX), Accelerate Diagnostics (AXDX), Biocept (BIOC), Magnachip Semiconductor (MX), Fluidigm (FLDM), Matinas BioPharma (MTNB), MicroVision (MVIS), Acasti Pharma (ACST), Bionano Genomics (BNGO) and Genius Brand...

What happen to BIOLASE stock?

Biolase announces reverse stock split Accordingly, the board of directors made a decision to effect a 1-for-25 reverse stock split effective 11:59 p.m. EST on April 28, 2022. It will reduce the company's outstanding shares of common stock to ~6.2 million from ~154 million.

Will BIOLASE go back up?

BIOLASE Inc (NASDAQ:BIOL) The 3 analysts offering 12-month price forecasts for BIOLASE Inc have a median target of 75.00, with a high estimate of 625.00 and a low estimate of 37.50. The median estimate represents a +1,361.99% increase from the last price of 5.13.

Is BIOLASE stock a good buy?

BIOLASE has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Is BIOLASE undervalued?

The Biolase stock price fell by -2.90% on the last day (Wednesday, 1st Jun 2022) from $4.83 to $4.69....Predicted Opening Price for Biolase of Thursday, June 2, 2022.Fair opening price June 2, 2022Current price$4.72$4.69 (Undervalued)

Is biolase a good company?

Biolase, overall is a good company. The growth potential is extremely political. The company culture/ creed, is well defined. It has good health benefits.

Is Uamy a good investment?

UAMY has a Quality Grade of D, ranking ahead of 24.25% of graded US stocks.

What does Biol company do?

BIOLASE, Inc. is a medical device company, which engages in the developing, manufacturing, marketing and sale of laser systems in dentistry and medicine. It operates through the Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products.

Is SOS a good stock?

SOS (NYSE:SOS) is down to 47 cents per share compared to over $7 per share in March 2021. The company recently sold over 35 million American depositary shares at 56 cents to raise new funds. Management's lack of vision and clarity makes SOS stock a tough buy.

Should I buy or sell BIOLASE stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last twelve months. There are currently 4 buy rati...

What is BIOLASE's stock price forecast for 2022?

4 analysts have issued 1-year price targets for BIOLASE's stock. Their forecasts range from $12.00 to $75.00. On average, they expect BIOLASE's sha...

How has BIOLASE's stock price performed in 2022?

BIOLASE's stock was trading at $9.75 at the start of the year. Since then, BIOL stock has decreased by 52.8% and is now trading at $4.60. View the...

When is BIOLASE's next earnings date?

BIOLASE is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for BIOLASE .

How were BIOLASE's earnings last quarter?

BIOLASE, Inc. (NASDAQ:BIOL) posted its quarterly earnings data on Thursday, May, 12th. The medical technology company reported ($0.81) earnings per...

When did BIOLASE's stock split? How did BIOLASE's stock split work?

BIOLASE shares reverse split on Friday, April 29th 2022. The 1-25 reverse split was announced on Friday, April 29th 2022. The number of shares owne...

What guidance has BIOLASE issued on next quarter's earnings?

BIOLASE updated its second quarter 2022 earnings guidance on Thursday, June, 9th. The company provided earnings per share (EPS) guidance of for the...

Who are BIOLASE's key executives?

BIOLASE's management team includes the following people: Mr. John R. Beaver , Pres, CEO & Director (Age 61, Pay $876.18k) Ms. Jennifer Bright ,...

What is Todd Norbe's approval rating as BIOLASE's CEO?

8 employees have rated BIOLASE CEO Todd Norbe on Glassdoor.com . Todd Norbe has an approval rating of 13% among BIOLASE's employees. This puts Tod...

What is a biolase?

BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that recent data published in two journals, the International Journal of Periodontics & Restorative Dentistry and Lasers in Medical Science, demonstrates BIOLASE's Waterlase Er,Cr:YSGG laser technology can be beneficial for the treatment of peri-implantitis in patients suffering from the inflammatory disease.

When is the BIOLASE earnings call 2021?

NEW YORK, NY / ACCESSWIRE / May 13, 2021 / BIOLASE, Inc. (NASDAQ:BIOL) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 13, 2021 at 4:30 PM Eastern Time.

What Happened With BIOL Stock

Nasdaq has told BIOLASE that it has until May 23, 2022 to get its share price above $1 and keep it there for a minimum of 10 consecutive trading days. If it can do that, it will regain compliance with the exchange and avoid being delisted. That extension buys BIOLASE some much-needed time to raise its stock from its current price.

Why It Matters

The extension by Nasdaq removes some immediate uncertainty surrounding BIOL stock. It also gives the Foothill Ranch, California-based company time to improve its financials, gain the confidence of investors, and push its stock price above the $1 minimum needed to remain on the Nasdaq. It is a positive development for BIOLASE in the near term.

Signals & Forecast

The Biolase stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock.

Support, Risk & Stop-loss

Biolase finds support from accumulated volume at $0.38 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

Is Biolase stock A Buy?

Biolase holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Insiders are very positive buying more shares than they are selling in Biolase

In the last 100 trades there were 11.23 million shares bought and 7.58 million shares sold. The last trade was done 13 days ago by Oloughlin Kathleen T who bough 90 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.

About Biolase

BIOLASE, Inc.,a medical device company, develops, manufactures, and markets laser systems in dentistry and medicine in the United States and internationally.

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

What is Biolase technology?

Biolase Technology (BIOL) operates in the medical laser technology space and targets the dental health industry . With returns of 145 percent YTD, BIOL stock has become popular with penny stock investors. What's the forecast for Biolase stock and should you buy it now?

Is Biolase a nonprofit?

Recently, Biolase struck a strategic partnership with Einstein Healthcare Network, which is a leading nonprofit healthcare system. The arrangement, focused on endodontist training, promises to bring more customers to Biolase and fuel its revenue growth. Biolase’s revenue jumped more than 30 percent sequentially in the fourth quarter of 2020 with newly acquired customers contributing nearly 80 percent of the sales.